The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Expected To Change From 2026 To 2030?
The antineutrophil cytoplasmic antibody (anca) associated vasculitis market has experienced substantial growth in recent years. It is projected to expand from $0.63 billion in 2025 to $0.68 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.7%. The market’s historical expansion can be attributed to advancements in autoimmune disease diagnostics, a rise in the use of corticosteroids and immunosuppressants, the enlargement of nephrology and rheumatology care services, increasing clinical understanding of rare vasculitis disorders, and the presence of standardized treatment protocols.
The market size for antineutrophil cytoplasmic antibody (anca) associated vasculitis is projected to experience robust expansion over the coming years. This market is anticipated to reach $0.95 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.6%. This projected growth during the forecast period is attributable to several factors, including the increasing development of targeted biologics, growing investments in rare disease research, the expansion of personalized treatment approaches, a heightened focus on relapse prevention strategies, and improved patient access to specialized care centers. Key trends expected during this period involve the increasing adoption of biologic therapies, an elevated focus on early and accurate diagnosis, the expanding utilization of targeted immunosuppressive treatments, the broadening of multidisciplinary disease management approaches, and a stronger emphasis on long-term disease monitoring.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Important Drivers Are Guiding The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Growth?
The ANCA-associated vasculitis market is anticipated to grow due to the increasing occurrence of autoimmune diseases, conditions where the immune system mistakenly targets healthy body cells and tissues as foreign invaders. The rising incidence of these diseases is linked to environmental and lifestyle factors, with heightened exposure to infections and pollutants significantly contributing by disrupting immune tolerance and triggering irregular immune responses. ANCA-associated vasculitis itself positively contributes to progress in autoimmune disease research and treatment by fostering targeted immunosuppressive therapies, improving early diagnosis, and refining disease management, which leads to better patient outcomes and greater insight into immune system regulation. For instance, the Impact of IBD Report 2023, released in September 2023 by the Canada-based Inflammatory Bowel Disease (IBD) Clinical and Research Centre, reported that in 2023, inflammatory bowel disease (IBD), an autoimmune condition, affected over 320,000 individuals in Canada, with a prevalence of 825 per 100,000 people. Forecasting an annual increase of 2.44%, it is projected that by 2035, approximately 470,000 Canadians, or 1.1% of the population, will be living with IBD. Consequently, the growing incidence of autoimmune diseases is set to propel the ANCA-associated vasculitis market.
Which Segment Classifications Are Used In The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Segment Analysis?
The antineutrophil cytoplasmic antibody (anca) associated vasculitis market covered in this report is segmented –
1) By Type: Granulomatosis With Polyangiitis (GPA Or Wegener’s), Microscopic Polyangiitis (MPA), Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss), Other Types
2) By Treatment: Immunosuppressants, Corticosteroids, Biologics, Other Treatments
3) By Diagnosis: Blood Tests, Biopsy, Imaging, Other Diagnosis
Subsegments:
1) By Granulomatosis With Polyangiitis (GPA or Wegener’s): Limited Granulomatosis With Polyangiitis, Severe Granulomatosis With Polyangiitis, Refractory Granulomatosis With Polyangiitis
2) By Microscopic Polyangiitis (MPA): Renal Microscopic Polyangiitis, Pulmonary Microscopic Polyangiitis, Neurological Microscopic Polyangiitis
3) By Eosinophilic Granulomatosis With Polyangiitis (EGPA or Churg-Strauss): Cardiac Eosinophilic Granulomatosis With Polyangiitis, Pulmonary Eosinophilic Granulomatosis With Polyangiitis, Neurological Eosinophilic Granulomatosis With Polyangiitis
4) By Other Types: Drug-Induced ANCA-Associated Vasculitis, Infection-Related ANCA-Associated Vasculitis, Overlap Syndrome ANCA-Associated Vasculitis
What Trends Are Influencing The Evolution Of The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market?
Major companies in the ANCA-associated vasculitis market are concentrating on developing innovative solutions, such as targeted therapies, to offer new treatment options for patients with this rare and severe condition. Targeted therapy for ANCA-associated vasculitis involves using specialized biologic agents to selectively inhibit immune system components responsible for inflammation and vascular damage, thereby reducing disease progression and minimizing treatment-related toxicity. For instance, in February 2023, Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a pharmaceutical company based in Switzerland, announced that Tavneos (avacopan) received approval from the Therapeutic Goods Administration (TGA), an Australian government regulatory agency. This approval is for the treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) when used in combination with a rituximab or cyclophosphamide-based regimen. This approval marks a significant advancement because Tavneos is the first targeted therapy specifically designed for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), which are the two primary forms of ANCA-associated vasculitis. By selectively inhibiting the complement C5a receptor (C5aR1), the therapy aids in controlling inflammation and disease progression while reducing dependence on high-dose glucocorticoids (steroids), which are known for severe long-term side effects.
Which Firms Are Contributing To The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Ecosystem?
Major companies operating in the antineutrophil cytoplasmic antibody (anca) associated vasculitis market are ChemoCentryx Inc, Amgen Inc, AstraZeneca Plc, GlaxoSmithKline plc, Novartis AG, Bristol-Myers Squibb Company, Travere Therapeutics Inc, F. Hoffmann-La Roche AG, Pfizer Inc, Sanofi SA, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, AbbVie Inc, UCB S.A., Bayer AG, Janssen Pharmaceuticals NV, Sobi AB, Alentis Therapeutics AG, InflaRx NV, NS Pharma Inc, Staidson Biopharmaceuticals Co Ltd, Genentech Inc, Regeneron Pharmaceuticals Inc, Mylan NV, Teva Pharmaceutical Industries Ltd, Biogen Inc, CSL Limited, Moderna Inc, Vertex Pharmaceuticals Inc.
Get The Full Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Report:
Which Geographic Region Dominates The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market?
North America was the largest region in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antineutrophil cytoplasmic antibody (anca) associated vasculitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market 2026, By The Business Research Company
Monoclonal Antibodies Market Report 2026
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report
Giant Cell Arteritis Market Report 2026
https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report
Monoclonal Antibodies Market Report 2026
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model